iLoF: Accelerating access to personalized medicine, from a drop of blood
- Portugal
- 5 min read
- Feb 16, 2021
- By Emanuela Ferraro
The iLoF founding team (L to R): CTO Joana Paiva, CEO Luís Valente, CSO Paula Sampaio and COO Mehak Mumtaz ©iLoF
Backed by Microsoft’s venture fund M12, Mayfield and Melinda Gates’s Pivotal Ventures, iLoF focuses on painless screening to facilitate disease detection, forecasting and drug development, from Alzheimer’s to Covid-19
Imagine getting your own personalized medical treatment for an illness – say, diabetes or cancer – created using all the biological, medical, behavioral and environmental information known about you. iLoF, a Porto- and Oxford-based precision medicine startup, is working to make that possible, from needing just a single drop of blood from the patient.
The goal: better predictions and preventative measures in early diagnostics, as well as accelerating and optimizing drug and treatment development – through inexpensive and non-invasive patient screening and stratification.
"iLoF w...
The goal: better predictions and preventative measures in early diagnostics, as well as accelerating and optimizing drug and treatment development – through inexpensive and non-invasive patient screening and stratification.
"iLoF w...
The rest of the content is only available if you are logged in.
We pride ourselves on the accuracy of our information and reporting. Please help us by letting us know of any incomplete or inaccurate information on our website.
MOST VIEWED